argenx SE is a biotechnology company that represents a strong set of values and corporate philosophy. With a focus on patients, collaboration, and innovation, argenx aims to transform the lives of people suffering from severe autoimmune diseases and cancer. The company is committed to developing breakthrough therapies based on its unique antibody engineering platform. By combining cutting-edge science, strategic partnerships, and a patient-centered approach, argenx strives to create meaningful impact in the healthcare industry. With its dedication to excellence and a relentless pursuit of scientific advancements, argenx SE has become a leading player in the biotech sector.

argenx SE is primarily present in various countries and regions around the world. The company has a global presence, with key operations and offices located in Europe, particularly in Belgium and the Netherlands. Additionally, argenx SE has expanded its footprint to North America, with offices and clinical development activities in the United States. Through its international presence, argenx SE aims to capitalize on the opportunities available in different markets and establish a strong presence in the biotechnology and pharmaceutical industry.

argenx SE has achieved several significant milestones in its history. It successfully completed a Phase 3 clinical trial for its product candidate efgartigimod, which demonstrated positive results in the treatment of generalized myasthenia gravis. The company also obtained breakthrough therapy designation from the U.S. FDA for efgartigimod in the same indication. Furthermore, argenx SE entered into strategic collaborations with multiple pharmaceutical companies to develop and commercialize its innovative antibody-based therapies. These partnerships include agreements with Janssen for cusatuzumab, Cilag GmbH International for ARGX-112, and Leo Pharma for ARGX-112. Overall, argenx SE has made significant strides in its quest to develop transformative medicines for patients.

argenx SE is a renowned biotechnology company with a rich history and significant accomplishments. Founded in 2008, argenx focuses on the discovery and development of innovative antibody-based therapeutics to benefit patients with severe autoimmune diseases and cancer. The company utilizes its unique Simple Antibody platform to engineer and manufacture differentiated therapeutic antibodies. Throughout its history, argenx has achieved numerous milestones, including successful clinical trials and collaborations with leading pharmaceutical companies. With its dedicated team of scientists and commitment to scientific excellence, argenx SE continues to make groundbreaking contributions in the field of biotechnology.

The main competitors of argenx SE in the market include companies such as Genmab A/S, Alexion Pharmaceuticals Inc., and MorphoSys AG.

argenx SE is primarily active in the pharmaceutical and biotechnology industries.

The business model of argenx SE revolves around developing and commercializing innovative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. With an emphasis on the discovery and development of uniquely differentiated antibody-based therapies, argenx combines its expertise in immunology and antibody engineering to target specific disease indications. The company focuses on both in-house discovery programs as well as collaborations with global partners to advance its pipeline of potential breakthrough treatments. By leveraging its expertise and strategic partnerships, argenx aims to bring transformative therapies to market and improve the lives of patients suffering from severe diseases.

argenx의 P/E 비율은 -783.55입니다.

argenx의 P/S 비율은 18.04입니다.

argenx에 대한 AlleAktien 품질 점수는 5/10입니다.

예상되는 argenx 매출은 2.06 조. USD입니다.

예상되는 argenx 이익은 -47.33 백만 USD입니다.

argenx SE is a biopharmaceutical company involved in the development and commercialization of therapeutic antibodies. The company operates in various areas, including antibody discovery, data collection, clinical development, manufacturing, and drug marketing. Their research focuses on autoimmune diseases, inflammatory diseases, and cancer. arGEN-X has successfully completed numerous clinical trials and has a wide range of products in various stages of development. The company also seeks partnerships with other biopharmaceutical companies to accelerate the development of new products. Their goal is to discover, develop, and market novel antibodies to treat seriously ill patients.

argenx은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

argenx의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

argenx의 ISIN은 NL0010832176입니다.

argenx의 WKN은 A11602입니다.

argenx의 티커는 ARGX.BR입니다.

지난 12개월 동안 argenx은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 argenx은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

argenx의 현재 배당 수익률은 입니다.

argenx은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

argenx은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

argenx은 '건강' 섹터에 속합니다.

argenx의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 argenx는 0 USD를 배당금으로 지급했습니다.

argenx의 배당금은 USD에 지급됩니다.